Trastuzumab deruxtecan (DS-8201) is a novel antibody-drug conjugate with a humanized anti-HER2 antibody, cleavable peptide linker, and potent topoisomerase I inhibitor payload that has been confirmed to be effective in multiple solid tumors, including CRC (Tsurutani et al., 2020). This evidence concerns the gene ERBB2 and colorectal carcinoma.